HE4 has proven utility as a serum biomarker in epithelial ovarian cancer (reviewed in [12]) and in 2009, the United States Food and Drug Agency (FDA) approved HE4 as an aid in monitoring recurrence or progressive disease in patients with epithelial ovarian cancer. Here, WFDC2 is linked to ovarian carcinoma.